iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. (ITOS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ITOS · as of Jun 30, 2025
Ownership Breakdown
142
Institutional Holders
▲ 8 vs Q1
$377.01M
Total Inst. Value
▲ $156.32M vs Q1
44.21M
Shares Outstanding
freeFloat 96.63%
37.81M
13F Shares Held
▲ 848,138 vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ITOS largest shareholders · institutional ownership
Q2 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ECOR1 CAPITAL, LLC biological products, (no diagnostic substances) | 10.69M | 24.54% | 24.54% | $106.57B | Aug 14, 2025 | NEW |
BLACKROCK, INC. biological products, (no diagnostic substances) | 4.57M | 10.50% | 10.50% | $45.61B | Aug 12, 2025 | ▲ 65.3K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 3.83M | 8.78% | 8.78% | $38.15B | Aug 14, 2025 | ▲ 1.14M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.66M | 3.82% | 3.82% | $16.59B | Aug 11, 2025 | ▼ 62.3K |
DIMENSIONAL FUND ADVISORS LP biological products, (no diagnostic substances) | 832.8K | 1.91% | 1.91% | $8.30B | Aug 12, 2025 | ▼ 348.5K |
BOXER CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 825.0K | 1.89% | 1.89% | $8.23B | Feb 17, 2026 | ▲ 825.0K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 703.5K | 1.61% | 1.61% | $7.02B | Aug 8, 2025 | ▲ 53.4K |
ORBIMED ADVISORS LLC biological products, (no diagnostic substances) | 700.0K | 1.61% | 1.61% | $6.98B | Aug 14, 2025 | NEW |
MARSHALL WACE, LLP biological products, (no diagnostic substances) | 611.6K | 1.40% | 1.40% | $6.10B | Aug 13, 2025 | ▲ 492.1K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 602.1K | 1.38% | 1.38% | $6.00B | Aug 13, 2025 | ▼ 43.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2025 vs prior quarter
Q2 2025
26
Increased
+5.15M shares15
New Positions
first time holders9
Decreased
−2.84M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.30M
+5.15M / −2.84M
Net new holders
+32
15 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ITOS insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
19
Sell transactions
0.00
Buy/Sell ratio
$2M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Call Matthew Chief Operating Officer | Aug 29, 2025 | D-Return | 135,937 | $7.05 | $958.4K | 0 | Form 4 ↗ |
Call Matthew Chief Operating Officer | Aug 29, 2025 | D-Return | 146,835 | $4.24 | $622.6K | 0 | Form 4 ↗ |
Call Matthew Chief Operating Officer | Aug 29, 2025 | D-Return | 66,170 | $2.95 | $195.2K | 0 | Form 4 ↗ |
Call Matthew Chief Operating Officer | Aug 29, 2025 | U-Tender | 161,898 | $10.05 | $1.63M | 0 | Form 4 ↗ |
Detheux Michel Chief Executive Officer | Aug 29, 2025 | D-Return | 52,700 | $6.16 | $324.6K | 0 | Form 4 ↗ |
Detheux Michel Chief Executive Officer | Aug 29, 2025 | D-Return | 444,815 | $7.05 | $3.14M | 0 | Form 4 ↗ |
Detheux Michel Chief Executive Officer | Aug 29, 2025 | D-Return | 185,000 | $4.24 | $784.4K | 0 | Form 4 ↗ |
Detheux Michel Chief Executive Officer | Aug 29, 2025 | U-Tender | 94,027 | $10.05 | $944.7K | 0 | Form 4 ↗ |
Lee David K director | Aug 29, 2025 | D-Return | 23,625 | $9.84 | $232.5K | 0 | Form 4 ↗ |
Feltquate David Chief Medical Officer | Aug 29, 2025 | U-Tender | 47,000 | $10.05 | $472.2K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
iTeos Therapeutics, Inc. (ITOS) is primarily owned by institutional investors, who hold approximately 85.5% of total shares outstanding. Company insiders own approximately 3.37%, while retail and public investors account for the remaining 11.08%.
The largest institutional shareholder of iTeos Therapeutics, Inc. is ECOR1 CAPITAL, LLC, holding approximately 10.69 million shares — equal to 24.54% of outstanding shares — as of June 30, 2025.
A total of 142 institutional investors currently hold ITOS stock, with a combined institutional value of approximately $377,012,279 as of the most recent 13F filing period.
Frequently asked questions
ITOS ownershipiTeos Therapeutics, Inc. (ITOS) is primarily owned by institutional investors, who hold approximately 85.5% of shares. The largest shareholder is ECOR1 CAPITAL, LLC with a 24.54% stake. Company insiders hold 3.37%. Data sourced from SEC Form 13F as of June 30, 2025.